Humoral response after BNT162b2 vaccination in hemodialysis patients
Not Applicable
- Conditions
- Chronic renal failure during hemodialysis
- Registration Number
- JPRN-UMIN000047032
- Lead Sponsor
- Fujita Memorial Hospital
- Brief Summary
Following vaccination, 97.6% of the hemodialysis group and 100% of the control group were positive for the anti-spike antibody. The median level of anti-spike antibody was 2,728.7 AU/mL (IQR, 1,024.2-7,688.2 AU/mL) in the hemodialysis group and 10,500 AU/ml (IQR, 9,346.1-2,4500 AU/mL) in the health care workers group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 294
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have had COVID-19 in the past
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibody acquisition rate by BNT162b2 vaccine
- Secondary Outcome Measures
Name Time Method Adverse events caused by BNT162b2 vaccine